Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy.

Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA.

Cancer Immunol Res. 2019 Sep 4. pii: canimm.0299.2019. doi: 10.1158/2326-6066.CIR-19-0299. [Epub ahead of print]

PMID:
31484655
2.

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh E, Ray S, Ngo LT, Kivitz S, Pasetto A, Yossef R, Lowery FJ, Goff SL, Lo W, Cafri G, Deniger DC, Malekzadeh P, Ahmadzadeh M, Wunderlich JR, Somerville RPT, Rosenberg SA.

Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.

PMID:
31164343
3.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.

Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA.

J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.

PMID:
30882547
4.

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.

Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC.

J Clin Invest. 2019 Mar 1;129(3):1109-1114. doi: 10.1172/JCI123791. Epub 2019 Feb 4. No abstract available.

5.

Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.

Lo W, Parkhurst M, Robbins PF, Tran E, Lu YC, Jia L, Gartner JJ, Pasetto A, Deniger D, Malekzadeh P, Shelton TE, Prickett T, Ray S, Kivitz S, Paria BC, Kriley I, Schrump DS, Rosenberg SA.

Cancer Immunol Res. 2019 Apr;7(4):534-543. doi: 10.1158/2326-6066.CIR-18-0686. Epub 2019 Feb 1. Review.

6.

Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.

Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA.

Nat Commun. 2019 Jan 25;10(1):449. doi: 10.1038/s41467-019-08304-z.

7.

Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity.

Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanović S, Robbins PF, Rosenberg SA.

Sci Immunol. 2019 Jan 11;4(31). pii: eaao4310. doi: 10.1126/sciimmunol.aao4310.

8.

Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.

Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA.

JCI Insight. 2018 Oct 4;3(19). pii: 122467. doi: 10.1172/jci.insight.122467.

9.

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.

Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA.

Nat Med. 2018 Jun;24(6):724-730. doi: 10.1038/s41591-018-0040-8. Epub 2018 Jun 4.

10.

T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.

Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, Wunderlich JR, Danforth DN, Somerville RPT, Rosenberg SA.

Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.

PMID:
29853601
11.

An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.

Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC, Rosenberg SA.

Mol Ther. 2018 Feb 7;26(2):379-389. doi: 10.1016/j.ymthe.2017.10.018. Epub 2017 Oct 28.

12.

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA.

J Clin Oncol. 2017 Oct 10;35(29):3322-3329. doi: 10.1200/JCO.2017.74.5463. Epub 2017 Aug 15.

13.

Tumor-Infiltrating Lymphocyte Therapy and Neoantigens.

Robbins PF.

Cancer J. 2017 Mar/Apr;23(2):138-143. doi: 10.1097/PPO.0000000000000267. Review.

PMID:
28410302
14.

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.

Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS.

Science. 2017 Apr 14;356(6334):200-205. doi: 10.1126/science.aak9510.

15.

Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.

Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RPT, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, Wunderlich JR, Zheng Z, Lu YC, Robbins PF, Rosenberg SA, Goff SL, Feldman SA.

Clin Cancer Res. 2017 Aug 1;23(15):4347-4353. doi: 10.1158/1078-0432.CCR-16-1423. Epub 2017 Apr 4.

16.

T-Cell Transfer Therapy Targeting Mutant KRAS.

Rosenberg SA, Tran E, Robbins PF.

N Engl J Med. 2017 Feb 16;376(7):e11. No abstract available.

17.

'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Tran E, Robbins PF, Rosenberg SA.

Nat Immunol. 2017 Feb 15;18(3):255-262. doi: 10.1038/ni.3682. Review.

18.

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA.

N Engl J Med. 2016 Dec 8;375(23):2255-2262.

19.

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.

Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, Gartner J, Trebska-McGowan K, Crystal JS, Rosenberg SA.

Cancer Immunol Res. 2016 Sep 2;4(9):734-43. doi: 10.1158/2326-6066.CIR-16-0001. Epub 2016 Jun 28.

20.

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.

Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF.

Cancer Immunol Res. 2016 Aug;4(8):669-78. doi: 10.1158/2326-6066.CIR-15-0215. Epub 2016 Jun 16.

21.

Targeting neoantigens for cancer immunotherapy.

Lu YC, Robbins PF.

Int Immunol. 2016 Jul;28(7):365-70. doi: 10.1093/intimm/dxw026. Epub 2016 May 19. Review.

22.

Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.

Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF.

J Immunother. 2016 Jun;39(5):191-201. doi: 10.1097/CJI.0000000000000123.

23.

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA.

Mol Ther. 2016 Jun;24(6):1078-1089. doi: 10.1038/mt.2016.51. Epub 2016 Mar 5.

24.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA.

Nat Med. 2016 Apr;22(4):433-8. doi: 10.1038/nm.4051. Epub 2016 Feb 22.

PMID:
26901407
25.

Cancer immunotherapy targeting neoantigens.

Lu YC, Robbins PF.

Semin Immunol. 2016 Feb;28(1):22-7. doi: 10.1016/j.smim.2015.11.002. Epub 2015 Nov 30. Review.

26.

T-Cell Receptor-Transduced T Cells: Clinical Experience.

Robbins PF.

Cancer J. 2015 Nov-Dec;21(6):480-5. doi: 10.1097/PPO.0000000000000160. Review.

PMID:
26588680
27.

Immunogenicity of somatic mutations in human gastrointestinal cancers.

Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA.

Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.

28.

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Clin Invest. 2015 Oct 1;125(10):3981-91. doi: 10.1172/JCI82416. Epub 2015 Sep 21.

29.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA.

Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.

30.

Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.

Feldman SA, Xu H, Black MA, Park TS, Robbins PF, Kochenderfer JN, Morgan RA, Rosenberg SA.

Hum Gene Ther Methods. 2014 Aug;25(4):253-60. doi: 10.1089/hgtb.2014.071.

31.

A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.

32.

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.

Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.

33.

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.

Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.

34.

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.

J Clin Invest. 2014 May;124(5):2246-59. doi: 10.1172/JCI73639. Epub 2014 Mar 25.

35.

A novel murine T-cell receptor targeting NY-ESO-1.

Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.

J Immunother. 2014 Apr;37(3):135-46. doi: 10.1097/CJI.0000000000000019.

PMID:
24598449
36.

Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma.

Aung PP, Liu YC, Ballester LY, Robbins PF, Rosenberg SA, Lee CC.

Hum Pathol. 2014 Feb;45(2):259-67. doi: 10.1016/j.humpath.2013.05.029. Epub 2013 Nov 27.

37.

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

Pos Z, Spivey TL, Liu H, Sommariva M, Chen J, Wunderlich JR, Parisi G, Tomei S, Ayotte BD, Stroncek DF, Malek JA, Robbins PF, Rivoltini L, Maio M, Chouchane L, Wang E, Marincola FM.

J Invest Dermatol. 2014 May;134(5):1389-1396. doi: 10.1038/jid.2013.495. Epub 2013 Nov 22.

38.

Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA.

Clin Cancer Res. 2014 Jan 15;20(2):331-43. doi: 10.1158/1078-0432.CCR-13-1736. Epub 2013 Nov 11.

39.

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF.

J Immunol. 2013 Jun 15;190(12):6034-42. doi: 10.4049/jimmunol.1202830. Epub 2013 May 20.

40.

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA.

Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.

41.

Helping tumor cells to die.

Robbins PF.

J Immunol. 2013 Mar 1;190(5):1897-8. doi: 10.4049/jimmunol.1300045. No abstract available.

42.

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.

J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903.

43.

Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Zhu S, Van den Eynde BJ, Coulie PG, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunother. 2012 Nov-Dec;35(9):680-8. doi: 10.1097/CJI.0b013e31827338ea.

44.

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.

Cancer Res. 2012 Dec 1;72(23):6119-29. doi: 10.1158/0008-5472.CAN-12-0588. Epub 2012 Oct 15.

45.

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN.

Oncoimmunology. 2012 Jul 1;1(4):409-418.

46.

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF.

Blood. 2012 Jun 14;119(24):5688-96. doi: 10.1182/blood-2011-10-386482. Epub 2012 May 3.

47.

NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.

Lai JP, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA, Miettinen MM, Lee CC.

Mod Pathol. 2012 Jun;25(6):854-8. doi: 10.1038/modpathol.2012.31. Epub 2012 Mar 2.

48.

Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.

Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH.

J Immunother. 2012 Feb-Mar;35(2):131-41. doi: 10.1097/CJI.0b013e31824300c7.

49.

An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):E323-31. doi: 10.1073/pnas.1101892108. Epub 2011 Jun 13.

50.

Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.

Huang J, Wang QJ, Yang S, Li YF, El-Gamil M, Rosenberg SA, Robbins PF.

J Immunother. 2011 May;34(4):327-35. doi: 10.1097/CJI.0b013e318216983d.

Supplemental Content

Loading ...
Support Center